Results 41 to 50 of about 28,157 (212)

Preliminary evidence on the safety profile of BNT162b2 (Comirnaty): new insights from data analysis in EudraVigilance and adverse reaction reports from an Italian health facility

Human Vaccines & Immunotherapeutics, 2021
The first vaccine against SARS-CoV-2 made available in Italy has been BNT162b2, the two-dose mRNA-based vaccine developed by Pfizer-BioNTech. The ASST Fatebenefratelli-Sacco hospital is located in one of the areas most affected by the pandemic, and to ...
Michele Gringeri, Giulia Mosini, Vera Battini, Gianluca Cammarata, Greta Guarnieri, Carla Carnovale, Emilio Clementi, Sonia Radice   +7 more
doaj   +1 more source

Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults

Human Vaccines & Immunotherapeutics, 2023
In this phase 4 study we assessed boosting with fractional doses of heterologous COVID-19 vaccines in Brazilian adults primed with two doses of CoronaVac (Sinovac/Butantan, São Paulo, Brazil) at least 4 months previously.
Sue Ann Costa Clemens, Natalie Marchevsky, Sarah Kelly, Sally Felle, Ahmed Eldawi, Rupetha Rajasingam, Rawan Mahmud, Teresa Lambe, Merryn Voysey, Isabela Gonzalez, Eveline Pipolo Milan, Maria Cleonice Justino, Sagida Bibi, Parvinder Aley, Ralf Clemens, Andrew J. Pollard   +15 more
doaj   +1 more source

Evaluation of the QuantiFERON SARS-CoV-2 assay to assess cellular immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in individuals with low and high humoral response

Human Vaccines & Immunotherapeutics, 2021
Vaccines against SARS-CoV-2 are known to be less immunogenic for some individuals, whereas others present notably high levels of antibody production.
Areti Tychala, Georgios Meletis, Eugenia Katsimpourlia, Ioanna Gkeka, Rodoula Dimitriadou, Eleni Sidiropoulou, Lemonia Skoura   +6 more
doaj   +1 more source

Adverse Reactions after BNT162b2 Messenger RNA Vaccination for Coronavirus Disease 2019 in Healthcare Workers Compared with Influenza Vaccination

Vaccines, 2023
This study aimed to compare adverse reactions following BNT162b2 and influenza vaccinations in healthcare workers. This study included healthcare workers who received the BNT162b2 vaccine and/or inactivated influenza vaccine, quadrivalent (IIV4), on 18 ...
A-Sol Kim, Sung-Min Kim, Ji-Eun Song, Soyoon Hwang, Eunkyung Nam, Ki Tae Kwon   +5 more
doaj   +1 more source

The Influence of Two Priming Doses of Different Anti-COVID-19 Vaccines on the Production of Anti-SARS-CoV-2 Antibodies After the Administration of the Pfizer/BioNTech Booster

Infection and Drug Resistance, 2022
Blanka Wolszczak Biedrzycka,1,2 Anna Bieńkowska,1,2 Elwira Smolińska-Fijołek,3 Grzegorz Biedrzycki,4 Justyna Dorf5 1Department of Psychology and Sociology of Health and Public Health, University of Warmia and Mazury in Olsztyn ...
Wolszczak Biedrzycka B, Bieńkowska A, Smolińska-Fijołek E, Biedrzycki G, Dorf J   +4 more
doaj  

SARS-CoV-2 S-RBD IgG & Neutralizing antibodies among different categories of health care workers post third dose BNT162b2 mRNA COVID-19 vaccine

Human Vaccines & Immunotherapeutics, 2023
Neutralizing antibodies (NTAb) play a significant role in preventing and protecting against SARS-CoV-2 virus infection. Identifying NTAb is undoubtedly imperative in understanding the immunity toward COVID-19 better.
Wan Muhammad Azfar Wan Shuaib, Izzatul Aliaa Badaruddin, Munirah Mansor, Sharifah Azura Salleh, Mohd Rohaizat Hassan, Steward Lindong, Shahril Nizam Samad, Hanita Othman   +7 more
doaj   +1 more source

Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line

Current Issues in Molecular Biology, 2022
Preclinical studies of COVID-19 mRNA vaccine BNT162b2, developed by Pfizer and BioNTech, showed reversible hepatic effects in animals that received the BNT162b2 injection.
Markus Aldén, Francisko Olofsson Falla, Daowei Yang, Mohammad Barghouth, Cheng Luan, Magnus Rasmussen, Yang De Marinis   +6 more
doaj   +1 more source

Hemophagocytic Lymphohistiocytosis Following BNT162b2 mRNA COVID-19 Vaccination

Vaccines, 2022
Although serious adverse events have remained uncommon, cases of myocarditis induced by messenger RNA (mRNA) COVID-19 vaccines have been reported. Here, we presented a rare but potentially fatal disorder, hemophagocytic lymphohistiocytosis, in a 14-year-old previously healthy adolescent after BNT162b2 mRNA vaccination.
Ting-Yu Lin, Yun-Hsuan Yeh, Li-Wen Chen, Chao-Neng Cheng, Chen Chang, Jun-Neng Roan, Ching-Fen Shen   +6 more
openaire   +3 more sources

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization [PDF]

Nature, 2021
Abstract The emergence of the SARS-CoV-2 variant of concern Omicron (Pango lineage B.1.1.529), first identified in Botswana and South Africa, may compromise vaccine effectiveness and lead to re-infections 1 .
Sandile Cele, Laurelle Jackson, David S. Khoury, Khadija Khan, Thandeka Moyo-Gwete, Houriiyah Tegally, James Emmanuel San, Deborah Cromer, Cathrine Scheepers, Daniel G. Amoako, Farina Karim, Mallory Bernstein, Gila Lustig, Derseree Archary, Muneerah Smith, Yashica Ganga, Zesuliwe Jule, Kajal Reedoy, Shi-Hsia Hwa, Jennifer Giandhari, Jonathan M. Blackburn, Bernadett I. Gosnell, Salim S. Abdool Karim, Willem Hanekom, Mary-Ann Davies, Marvin Hsiao, Darren Martin, Koleka Mlisana, Constantinos Kurt Wibmer, Carolyn Williamson, Denis York, Rohen Harrichandparsad, Kobus Herbst, Prakash Jeena, Thandeka Khoza, Henrik Kløverpris, Alasdair Leslie, Rajhmun Madansein, Nombulelo Magula, Nithendra Manickchund, Mohlopheni Marakalala, Matilda Mazibuko, Mosa Moshabela, Ntombifuthi Mthabela, Kogie Naidoo, Zaza Ndhlovu, Thumbi Ndung’u, Nokuthula Ngcobo, Kennedy Nyamande, Vinod Patel, Theresa Smit, Adrie Steyn, Emily Wong, Anne von Gottberg, Jinal N. Bhiman, Richard J. Lessells, Mahomed-Yunus S. Moosa, Miles P. Davenport, Tulio de Oliveira, Penny L. Moore, Alex Sigal   +60 more
openaire   +5 more sources

Effectiveness of the first and the second dose of COVID-19 vaccines in Serbia during the first three months of rollout [PDF]

Srpski Arhiv za Celokupno Lekarstvo
Introduction/Objective. The main aim of this study was to assess COVID-19 vaccination effectiveness (VE) of BBIBP-CorV, Gam-COVID-Vac, BNT162b2, and ChAdOx1-nCoV-19 in Serbia during the first three months of rollout. Methods.
Đorđević Nataša, Matić Sanja, Milovanović Dragan, Stefanović Srđan, Popović Suzana, Todorović Danijela, Đurđević Predrag, Sazdanović Predrag, Antić Vasilije, Lončar Slavica, Bukumira Slavica, Radenković Marko, Šušteršić Tijana, Filipović Nenad, Baskić Dejan   +14 more
doaj   +1 more source